UnknownPhase 2NCT05654467

Study of a Novel Type 3 Oral Poliomyelitis Vaccine in Panama

Studying Poliomyelitis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
PATH
Principal Investigator
Xavier Saez-Llorens, MD
Cevaxin
Intervention
Novel Live Attenuated Type 3 Oral Poliomyelitis Vaccine (nOPV3)(biological)
Enrollment
1532 enrolled
Eligibility
4 years · All sexes
Timeline
20232025

Study locations (3)

Collaborators

Bill and Melinda Gates Foundation · PT Bio Farma · Centers for Disease Control and Prevention · Technical Resources International, Inc. (TRI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05654467 on ClinicalTrials.gov

Other trials for Poliomyelitis

Additional recruiting or active studies for the same condition.

See all trials for Poliomyelitis

← Back to all trials